Home » Drug Information » Recently Approved Drugs » 1998
Medical Areas: Dermatology/Plastic Surgery | Immunology/Infectious Diseases | Pulmonary/Respiratory Diseases
Drug Information
The following information is obtained from various newswires, published
medical journal articles, and medical conference presentations.
Company: Sanofi Pharmaceuticals
Approval Status: Approved March 1998
Treatment Area: acute bacterial exacerbations
Dynabac, a member of the newer macrolide group of antibiotics,
has received approval for expanded coverage within certain
indications, including the treatment of acute bacterial
exacerbations of chronic bronchitis and uncomplicated skin and skin
structure infections. Dynabac remains a once-a-day therapy.
The most common side effects were gastrointestinal, including
abdominal pain, nausea, and diarrhea.
